BRPI1014631A2 - peptídeos e seus usos. - Google Patents
peptídeos e seus usos.Info
- Publication number
- BRPI1014631A2 BRPI1014631A2 BRPI1014631-8A BRPI1014631A BRPI1014631A2 BR PI1014631 A2 BRPI1014631 A2 BR PI1014631A2 BR PI1014631 A BRPI1014631 A BR PI1014631A BR PI1014631 A2 BRPI1014631 A2 BR PI1014631A2
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- variant
- effective
- peptides
- present
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010061246 Intervertebral disc degeneration Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000018180 degenerative disc disease Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 206010061989 glomerulosclerosis Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000021600 intervertebral disc degenerative disease Diseases 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
peptídeos e seus usos a presente invenção oferece um peptídeo compreendendo uma sequência de aminoácidos de seq lo no: 1, um variante e um sal farmaceuticamente aceitável. um novo peptídeo da presente invenção, variante do mesmo e seu sal são eficazes no tratamento e/ou prevenção de doenças discais degenerativas, no tratamento da fibrose em órgãos corporais, no tratamento do câncer e/ou glomerulosclerose, e são eficazes na inibição do sinal tgf-beta 1 .
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020090075142A KR100983182B1 (ko) | 2009-08-14 | 2009-08-14 | 신규 펩타이드 및 그 용도 |
| KR10-2009-0075142 | 2009-08-14 | ||
| PCT/KR2010/000907 WO2011019123A1 (en) | 2009-08-14 | 2010-02-12 | Novel peptide and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI1014631A2 true BRPI1014631A2 (pt) | 2019-04-16 |
| BRPI1014631B1 BRPI1014631B1 (pt) | 2022-01-18 |
Family
ID=43010309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1014631-8A BRPI1014631B1 (pt) | 2009-08-14 | 2010-02-12 | Composições que compreendem um peptídeo que inibe a sinalização de tgf-beta 1 em um veículo farmaceuticamente aceitável e usos do dito peptídeo para tratar ou prevenir doenças discais degenerativas, fibrose em órgãos corporais, câncer e glomerulosclerose |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8691749B2 (pt) |
| EP (1) | EP2464656B1 (pt) |
| JP (1) | JP5475131B2 (pt) |
| KR (1) | KR100983182B1 (pt) |
| CN (1) | CN102482323B (pt) |
| AU (1) | AU2010283169C1 (pt) |
| BR (1) | BRPI1014631B1 (pt) |
| CA (1) | CA2770018C (pt) |
| ES (1) | ES2548527T3 (pt) |
| MX (1) | MX2011013972A (pt) |
| PL (1) | PL2464656T3 (pt) |
| RU (1) | RU2498992C1 (pt) |
| SG (1) | SG178260A1 (pt) |
| WO (1) | WO2011019123A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101434465B1 (ko) | 2012-07-16 | 2014-08-26 | 조선대학교산학협력단 | 바실러스 아밀로리쿼파시엔스 ｅｍｌ－ｃａｐ３으로부터 분리된 신규한 항균 및 항진균 펩타이드 및 이의 용도 |
| KR101995768B1 (ko) * | 2019-03-13 | 2019-07-03 | (주)엔솔바이오사이언스 | 신규 펩타이드 및 그 용도 |
| CN110613837A (zh) * | 2019-10-24 | 2019-12-27 | 内蒙古医科大学第二附属医院 | TGF-β在制备预防或治疗腰椎间盘突出药物中的应用 |
| KR20230167231A (ko) | 2022-05-31 | 2023-12-08 | 주식회사 엔솔바이오사이언스 | 염형태 변형 펩타이드의 제조방법 및 그를 이용하여 제조된 펩타이드 |
| KR20240000395A (ko) * | 2022-06-22 | 2024-01-02 | 주식회사 유씨아이테라퓨틱스 | TGF-β 신호전달을 억제할 수 있는 신규한 펩타이드 및 이의 용도 |
| KR20240082202A (ko) * | 2022-11-11 | 2024-06-10 | 주식회사 유씨아이테라퓨틱스 | 유전자 조작된 세포 및 이의 용도 |
| WO2025089465A1 (ko) * | 2023-10-27 | 2025-05-01 | 주식회사 엔솔바이오사이언스 | 펩타이드 제조방법 및 그를 이용하여 제조된 펩타이드 |
| WO2025089467A1 (ko) * | 2023-10-27 | 2025-05-01 | 주식회사 엔솔바이오사이언스 | 염형태 변형 펩타이드의 제조방법 및 그를 이용하여 제조된 펩타이드 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6509314B1 (en) * | 1988-06-28 | 2003-01-21 | The Burnham Institute | Methods of preventing or reducing scarring with decorin or biglycan |
| US5654270A (en) | 1988-06-28 | 1997-08-05 | La Jolla Cancer Research Foundation | Use of fibromodulin to prevent or reduce dermal scarring |
| DE69232946T2 (de) | 1991-11-14 | 2003-12-18 | La Jolla Cancer Research Foundation, La Jolla | Inhibitoren von zellregulationsfaktoren und verfahren zur verhütung oder verminderung von narbenbildung |
| ES2146552B1 (es) * | 1998-11-24 | 2001-04-16 | Inst Cientifico Tecnol Navarra | Peptidos inhibidores de tgf/31 |
| US20040031072A1 (en) * | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
| US6864236B1 (en) * | 1999-11-18 | 2005-03-08 | Brown University Research Foundation | Biglycan and related therapeutics and methods of use |
| ATE420654T1 (de) * | 2001-08-15 | 2009-01-15 | Univ Brown Res Found | Behandlung von muskeldystrophien und verwandter erkrankungen |
| EP1485116A4 (en) * | 2002-02-27 | 2006-06-07 | Univ Wake Forest | ANGIOTENSIN- (1-7) AND AGONISTS OF ANGIOTENSIN- (1-7) FOR THE INHIBITION OF GROWTH OF CANCER CELLS |
| US20080107705A1 (en) * | 2004-08-04 | 2008-05-08 | Spinal Therapies Llc | Chymopapain Isoenzymes, Compositions, and Uses Thereof |
| WO2008054764A2 (en) * | 2006-10-31 | 2008-05-08 | George Mason Intellectual Properties, Inc. | Biomarkers for colorectal cancer |
| WO2009002472A1 (en) | 2007-06-22 | 2008-12-31 | University Of Georgia Research Foundation, Inc. | Novel secreted proteins of adipocytes for diagnostic purposes |
-
2009
- 2009-08-14 KR KR1020090075142A patent/KR100983182B1/ko active Active
-
2010
- 2010-02-12 MX MX2011013972A patent/MX2011013972A/es active IP Right Grant
- 2010-02-12 RU RU2012108179/10A patent/RU2498992C1/ru active
- 2010-02-12 EP EP10808272.8A patent/EP2464656B1/en active Active
- 2010-02-12 CA CA2770018A patent/CA2770018C/en active Active
- 2010-02-12 AU AU2010283169A patent/AU2010283169C1/en active Active
- 2010-02-12 US US13/389,051 patent/US8691749B2/en active Active
- 2010-02-12 ES ES10808272.8T patent/ES2548527T3/es active Active
- 2010-02-12 PL PL10808272T patent/PL2464656T3/pl unknown
- 2010-02-12 BR BRPI1014631-8A patent/BRPI1014631B1/pt active IP Right Grant
- 2010-02-12 WO PCT/KR2010/000907 patent/WO2011019123A1/en not_active Ceased
- 2010-02-12 JP JP2012523550A patent/JP5475131B2/ja active Active
- 2010-02-12 SG SG2012007910A patent/SG178260A1/en unknown
- 2010-02-12 CN CN201080035995.5A patent/CN102482323B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010283169B2 (en) | 2015-11-12 |
| US8691749B2 (en) | 2014-04-08 |
| KR100983182B1 (ko) | 2010-09-20 |
| PL2464656T3 (pl) | 2015-12-31 |
| JP2013501711A (ja) | 2013-01-17 |
| US20120190625A1 (en) | 2012-07-26 |
| CA2770018C (en) | 2015-11-24 |
| SG178260A1 (en) | 2012-03-29 |
| EP2464656A1 (en) | 2012-06-20 |
| WO2011019123A1 (en) | 2011-02-17 |
| MX2011013972A (es) | 2012-04-02 |
| BRPI1014631B1 (pt) | 2022-01-18 |
| ES2548527T3 (es) | 2015-10-19 |
| JP5475131B2 (ja) | 2014-04-16 |
| CN102482323B (zh) | 2014-05-14 |
| CA2770018A1 (en) | 2011-02-17 |
| RU2012108179A (ru) | 2013-09-20 |
| AU2010283169A1 (en) | 2012-03-29 |
| RU2498992C1 (ru) | 2013-11-20 |
| CN102482323A (zh) | 2012-05-30 |
| EP2464656A4 (en) | 2013-06-12 |
| EP2464656B1 (en) | 2015-07-01 |
| AU2010283169C1 (en) | 2016-03-03 |
| HK1168363A1 (en) | 2012-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1014631A2 (pt) | peptídeos e seus usos. | |
| IL262976A (en) | Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof | |
| JP2012176978A5 (pt) | ||
| IN2012DN02981A (pt) | ||
| PE20130648A1 (es) | Tratamiento del sindrome de sanfilippo tipo b | |
| MX340541B (es) | Secuencias de aminoacidos mejoradas dirigidas contra virus sincitial respiratorio humano y polipeptidos que comprenden las mismas para la prevencion y/o tratamiento de infecciones del tracto respiratorio. | |
| WO2011036442A3 (en) | Thrombin c- terminal polypeptides and uses thereof for treating inflammation coagulation disorders | |
| UA100127C2 (ru) | Пептид cdh3 и лекарственное средство, содержащее его | |
| WO2015024667A8 (en) | Method for increasing expression of rna-encoded proteins | |
| EP2808029A3 (en) | Combination therapies using cyclosporine and aromatic cationic peptides | |
| NZ587105A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
| WO2008118017A3 (en) | Prame derived peptides and immunogenic compositions comprising these | |
| HK1201727A1 (en) | Anticancer fusion protein | |
| BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
| NZ608502A (en) | Polypeptides that bind to human complement component c5 | |
| JP2015510393A5 (pt) | ||
| ES2656562T3 (es) | Derivado de polimixina y usos del mismo | |
| AR068020A1 (es) | Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico | |
| JP2006506942A5 (pt) | ||
| WO2008093058A3 (en) | Peptides and their use | |
| NZ610620A (en) | Inhibitors of apoptosis and uses thereof | |
| WO2013096868A3 (en) | Saposin-a derived peptides and uses thereof | |
| JP2010536714A5 (pt) | ||
| WO2011022056A3 (en) | PEPTIDE MODULATORS OF THE δPKC INTERACTION WITH THE D SUBUNIT OF F1FO ATP SYNTHASE/ATPASE AND USES THEREOF | |
| WO2008040190A8 (fr) | Petits peptides pour anti-angiogenèse et utilisation de ceux-ci |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/02/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |